Cap-assisted endoscopic sclerotherapy for XXXX : Methods, feasibility and efficacy.

@entity1 @entity81 @entity1127 @entity6713
AIM: To evaluate the methodology, feasibility, safety and efficacy of a novel method called cap-assisted endoscopic sclerotherapy (CAES) for internal @entity6713 . METHODS: A pilot study on CAES for grade   I   to III internal @entity6713 was performed. Colon and terminal ileum examination by colonoscopy was performed for all @entity1 before starting CAES. Polypectomy and excision of anal papilla @entity81 were performed if @entity1127 or anal papilla @entity81 were found and assessed to be suitable for resection under endoscopy. CAES was performed based on the requirement of the cap, endoscope, disposable endoscopic long injection needle, enough insufflated air and sclerosing agent. RESULTS: A total of 30 @entity1 with grade   I   to III internal @entity6713 was included. The follow-up was more than four weeks. No bleeding was observed after CAES. One (3.33%) @entity1 claimed mild tenesmus within four days after CAES in that an endoscopist performed this procedure for the first time. One hundred percent of @entity1 were satisfied with this novel procedure, especially for those @entity1 who underwent CAES in conjunction with polypectomy or excision of anal papilla @entity81 . CONCLUSION: CAES as a novel endoscopic sclerotherapy should be a convenient, safe and effective flexible endoscopic therapy for internal @entity6713 .
